Fas gene promoter -670 polymorphism in gynecological cancer

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 1, 2006, Pages 179-182

  Ueda, M ^a   Terai, Y ^a   Kanda, K ^a   Kanemura, M ^a   Takehara, M ^a   Yamaguchi, H ^a   Nishiyama, K ^a   Yasuda, M ^a   Ueki, M ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Fas; Gynecological cancer; Polymorphism

Indexed keywords

FAS ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIGENS, CD95; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENITAL NEOPLASMS, FEMALE; GENOTYPE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RISK; UTERINE CERVICAL NEOPLASMS;

EID: 33645375390     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00505.x     Document Type: Article

References (18)

1. Evan GI Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001 411 342 8.
2. Lowe SW Lin AW. Apoptosis in cancer. Carcinogenesis 2000 21 485 95.
3. Nagata S Golstein P. The Fas death factor. Science 1995 267 1449 56.
4. Suda T Takahashi T Golstein P Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993 75 1169 78.
5. Huang QR Morris D Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997 34 577 82.
6. Sibley K Rollinson S Allan JM et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003 63 4327 30.
7. Kanemitsu S Ihara K Saifddin A et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002 29 1183 8.
8. Huang QR Danis V Lassere M Edmonds J Manolios N. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 1999 38 645 51.
9. Lai HC Sytwu HK Sun CA et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003 103 221 5.
10. Engelmark MT Renkema KY Gyllensten UB. No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Int J Cancer 2004 112 1084 5.
11. Lee YH Kim YR Ji JD Sohn J Song GG. Fas promoter -670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus. J Rheumatol 2001 28 2008 11.
12. Ueda M Gemmill RM West J et al. Mutations of the β- and γ-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer 2001 85 64 8.
13. Dybikowska A Sliwinski W Emerich J Podhajska AJ. Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int J Mol Med 2004 14 475 8.
14. Niino M Kikuchi S Fukazawa T Miyagishi R Yabe I Tashiro K. An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis. BMC Neurol 2002 2 8 12.
15. Contreras DN Krammer PH Potkul RK et al. Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J Immunother 2000 23 67 74.
16. Das H Koizumi T Sugimoto T et al. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 2000 82 1682 8.
17. Sun T Miao X Zhang X Tan W Xiong P Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous cell carcinoma. J Natl Cancer Inst 2004 96 1030 6.
18. Ueda M Hung YC Terai Y et al. Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 2005 98 129 33.